Enzolytics Inc (ENZC)

[OTCShotCaller]

Enzolytics Inc (OTCMKTS: ENZC) is making a powerful move up the charts on a massive surge of volume after the Company announced on Sept 15, 2020 the execution of a non-binding LOI to merge with BioClonetics Immunotherapeutics, Inc. a biotech company located in Dallas Texas. BioClonetics is in the final stage of development of a parent monoclonal antibody (“mAbs”) (designated as Clone 3), which is non-toxic and has shown in initial in-vitro testing to be effective against greater than 95% of all strains of HIV. Nothing like this presently exists!

Subsequently, on Oct 1, 2020 Enzolytics, Inc. announced the addition of Charles Cotropia to the Company’s Board of Directors. ENZC entered into a Letter of Intent (the “LOI”) to merge with BioClonetics Immunotherapeutics, Inc. (“BCLS” or “BioClonetics”), a biotech company located in Dallas Texas, on September 15, 2020. In addition, the Company announces that Harry Zhabilov, CEO of ENZC will also be joining the Board of Directors of BioClonetics. The additions to the boards of ENZC and BCLS is expected to assist each group to complete their due diligence more rapidly in order to move to definitive agreements and prepare for a smooth transition upon completion of the transaction.

https://apnews.com/press-release/accesswire/virus-outbreak-science-business-technology-products-and-services-69781e2bb428e88bec928efd88e1411e

The best NEWS in ALL of this is Dr. Cotropia holds an exclusive patent on Clone-3 Technology that Dr. Fauci attempted to steal from him some time ago by making overlapping claims to The U.S. Patent Office for the same thing but he did not prevail. (see link below)

https://aumag.org/2013/09/26/the-future-of-clone-3/

The gravity of this is absolutely incomprehensible for reason it defies all known clinical-pharmaceutical applications that have been brought to the global market thus far for treatment of AIDS/HIV.

This merger undoubtedly will represent the single greatest thrust in medical science for curing most strains of HIV there by dramatically reducing its impact on humanity rendering it "easily treated" if not cured!

Essentially, we're looking at "Disruption Technology" in motion here!

I have a professional clinical research background that includes bringing pharmaceuticals to market via randomized controlled clinical trials and believe I can make a significant contribution to this message board.

I just joined this forum today and will be posting insightful information from time to time that may help investors in this merger make an informed decision.

I can tell everyone this, I an have done my DD on these two companies and they are BOTH not only the "real deal" but they definitely have what it takes to become THE Global Leader in the space of AIDS/HIV treatment.

I can tell everyone here from experience from being in clinical research most of my professional life,they won't have any problem whatsoever obtaining any amount of funding they need from any and all sources to bring their scientific achievement to commercialization, and by far their stock will quickly transition to either NASDAQ or NYSE with a corresponding dramatic rise in the share price that will likely forward split several times.

My prediction is this stock will move to NASDAQ within 6 months of merger completion which I perceive is already a "done deal" soon to be announced, and when that happens the share price will foreseeably be trading in the $5-$10 range at least a year BEFORE their Phase IV patient trials are complete but with preliminary positive findings. Soon after, the Share Price will soar even higher with anticipated FDA Approval.

Post FDA approval I see this company stock trading easily in the $100-$500 range within 12 months of commercialization IF they are not bought out before then by one of the majors like Merk, Pfizer, etc.

Watch for my posts, I have gathered A LOT of Intel on this Company that includes some very promising numbers! Hint: $7 per share is not an unrealistic near term PPS, but I believe it will be trading on NASDAQ by then.